Livongo (formerly Retrofit) is digital healthcare company offering mobile, online and personalized, real-time support for people at risk for or living with chronic conditions.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/23/2018 | Series E | $105MM | $xx.xx | $796.49MM | General Catalyst, KinnevikMerck, Global Health Innovation Fund, Wanxiang America, M12, Echo Health Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Kleiner Perkins and Draper Fisher Jurvetson Management | |
Price per Share
$xx.xx
Shares Outstanding
12,655,481
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
General Catalyst, KinnevikMerck, Global Health Innovation Fund, Wanxiang America, M12, Echo Health Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Kleiner Perkins and Draper Fisher Jurvetson Management
|
||||||
03/16/2017 | Series D | $52.5MM | $xx.xx | $320MM | General Catalyst Partners and Kinnevik, Singapore Economic Development Board, American Investment Holdings, EDB Investments, Kleiner Perkins Caufield & Byers, Microsoft Ventures and undisclosed existing investors | |
Price per Share
$xx.xx
Shares Outstanding
11,773,937
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
General Catalyst Partners and Kinnevik, Singapore Economic Development Board, American Investment Holdings, EDB Investments, Kleiner Perkins Caufield & Byers, Microsoft Ventures and undisclosed existing investors
|
||||||
04/22/2016 | Series C | $49.5MM | $xx.xx | $194MM | Glen Tullman, Merck Global Health Innovation Fund, Cowen Private Investments, Healthcare Growth Partners, Sapphire Ventures, Zaffre Investments, Wanxiang America Corporation, General Catalyst, Kleiner Perkins Caufield & Byers, DFJ and 7wire Ventures | |
Price per Share
$xx.xx
Shares Outstanding
14,856,832
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Glen Tullman, Merck Global Health Innovation Fund, Cowen Private Investments, Healthcare Growth Partners, Sapphire Ventures, Zaffre Investments, Wanxiang America Corporation, General Catalyst, Kleiner Perkins Caufield & Byers, DFJ and 7wire Ventures
|
||||||
04/09/2015 | Series B | $20MM | $xx.xx | $87MM | Kleiner Perkins Caufield & Byers, Draper Fisher Jurvetson and General Catalyst partner | |
Price per Share
$xx.xx
Shares Outstanding
8,934,953
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Kleiner Perkins Caufield & Byers, Draper Fisher Jurvetson and General Catalyst partner
|
||||||
05/22/2007 | Series A | $10.65MM | $xx.xx | $30MM | General Catalyst Partners and Slow Ventures | |
Price per Share
$xx.xx
Shares Outstanding
10,394,306
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
General Catalyst Partners and Slow Ventures
|